HR Execs on the Move

Everest Clinical Research

www.ecrscorp.com

 
Everest Clinical Research ("Everest") is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. We serve some of the best-known companies and work with many of the most advanced drugs, biologics, and medical devices in development today.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.ecrscorp.com
  • 675 Cochrane Drive East Tower, 4th Floor
    Markham, ON CAN L3R 0B8
  • Phone: 905.752.5222

Executives

Name Title Contact Details
Tom Kotsopoulos
Associate Director of Human Resources Profile

Similar Companies

IriSys Inc

IriSys Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

H.D. Smith Wholesale Drug Co.

Headquartered in Springfield, Illinois, H. D. Smith is among the largest national full-line, full-service wholesalers providing a complete line of pharmaceuticals, OTCs, HBAs, home healthcare products, durable medical equipment, seasonal merchandise and a wide array of marketing programs to retail pharmacies, regional chains and health systems.

TetraGenx

TetraGenx is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

KidMed VA

Get expert pediatric urgent care for your child. Find the KidMed location nearest you, or learn more about what makes us the regions leading choice.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.